Marc R. Schneebaum
Director/Board Member at Stemina Biomarker Discovery, Inc.
Profile
Marc R.
Schneebaum is currently the Director at Stemina Biomarker Discovery, Inc. He previously held positions as the President, Chief Executive Officer & Director at Senseonics, Inc. from 1997 to 2010, President, Chief Executive Officer & Director at Predictive Biosciences, Inc. in 2012, Independent Director at GenVec, Inc. from 2007 to 2017, Director at Science, Inc., Director at March of Dimes of Maryland, Senior VP, Chief Financial & Accounting Officer at Synta Pharmaceuticals Corp.
from 2015 to 2016, Senior Manager at KPMG LLP, Chief Financial Officer & Senior VP-Administration at Genetic Therapy, Inc. from 1991 to 1997, and Vice President at Alex.
Brown & Sons, Inc. from 1987 to 1991.
He also served as the CFO, Principal Accounting Officer & Senior VP at Madrigal Pharmaceuticals, Inc. from 2016 to 2021, and is currently the Chief Financial Officer at Avalyn Pharma, Inc. Mr. Schneebaum obtained his undergraduate degree from the University of Maryland.
Marc R. Schneebaum active positions
| Companies | Position | Start |
|---|---|---|
Stemina Biomarker Discovery, Inc.
 Stemina Biomarker Discovery, Inc. BiotechnologyHealth Technology Stemina Biomarker Discovery, Inc. engages in the development and commercialization of molecular biomarkers to improve drug safety and human health. Its products and services include Cardio quickPredict, devTOX quickPredict, and TOXquickPredict. The company was founded by Elizabeth L. R. Donley and Gabriela G. Cezar in November 2006 and is headquartered in Madison, WI. | Director/Board Member | - |
Former positions of Marc R. Schneebaum
| Companies | Position | End |
|---|---|---|
Avalyn Pharma, Inc.
 Avalyn Pharma, Inc. Pharmaceuticals: MajorHealth Technology Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA. | Director of Finance/CFO | 01/05/2024 |
| MADRIGAL PHARMACEUTICALS, INC. | Director of Finance/CFO | 17/05/2021 |
| GENVEC INC | Director/Board Member | 16/06/2017 |
Synta Pharmaceuticals Corp.
 Synta Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA. | Director of Finance/CFO | 01/07/2016 |
Predictive Biosciences, Inc.
 Predictive Biosciences, Inc. Medical/Nursing ServicesHealth Services Predictive Biosciences is a fully-integrated developer of novel molecular diagnostic cancer assays, and a subspecialty, urology-focused provider of anatomic pathology laboratory products and services. The Company pioneered the Clinical Intervention Determining Diagnostic (CIDD) and Multi-Analyte Diagnostic Readout (MADR) approaches to cancer management, leveraging its portfolio of patented biomarkers and clinical algorithms. Based on these approaches, the Company is building a unique portfolio of assays that enable physicians to reliably determine the presence or absence of cancer with very high levels of confidence. Predictive Biosciences' first tests are targeted toward the growing bladder cancer and prostate cancer survivor populations and the large number of individuals undergoing clinical workups for these malignancies. Predictive Biosciences' corporate headquarters and innovation center is located in Lexington, Massachusetts. The Company's commercial division, OncoDiagnostic Laboratory (ODL), is located in Cleveland, Ohio. ODL is a Clinical Laboratory Improvement Act (CLIA)-certified anatomic pathology and molecular diagnostics lab with a national sales force serving urologists, gastroenterologists, dermatologists, gynecologists, and other subspecialty physicians. Founded in 2006, Predictive Biosciences is privately funded by Flybridge Capital Partners, Highland Capital Partners, Kaiser Permanente Ventures and New Enterprise Associates. | President | 01/01/2013 |
Training of Marc R. Schneebaum
| University of Maryland | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| MADRIGAL PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 11 |
|---|---|
GenVec, Inc.
 GenVec, Inc. Pharmaceuticals: MajorHealth Technology GenVec, Inc. operated as a clinical-stage gene delivery company, which engaged in the development of therapeutics and vaccines. The firm designs, tests, and manufactured adenoviral-based product candidates using its proprietary AdenoVerse platform. Its products included CGF166-Hearing Loss; GV2311-RSV Vaccine; and GV2207-HSV-2 Immunotherapeutic. The company was founded in December 1992 and was headquartered in Rockville, MD. | Health Technology |
Science, Inc.
 Science, Inc. Miscellaneous Commercial ServicesCommercial Services Science, Inc. provides media and marketing services. The company is headquartered in Bloomington, MN. | Commercial Services |
Synta Pharmaceuticals Corp.
Synta Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Synta Pharmaceuticals Corp. discovers, develops and commercializes pharmaceutical products. It focuses on the research, development and commercialization of oncology medicines that provides treatment to cancer patients. The company is also developing a proprietary platform for delivery of anti-cancer drugs directly to tumor cells, known as Hsp90-inhibitor drug conjugates. Synta Pharmaceuticals was founded by Safi R. Bahcall and Lan-Bo Chen in March 2000 and is headquartered in Lexington, MA. | Health Technology |
Stemina Biomarker Discovery, Inc.
Stemina Biomarker Discovery, Inc. BiotechnologyHealth Technology Stemina Biomarker Discovery, Inc. engages in the development and commercialization of molecular biomarkers to improve drug safety and human health. Its products and services include Cardio quickPredict, devTOX quickPredict, and TOXquickPredict. The company was founded by Elizabeth L. R. Donley and Gabriela G. Cezar in November 2006 and is headquartered in Madison, WI. | Health Technology |
Avalyn Pharma, Inc.
Avalyn Pharma, Inc. Pharmaceuticals: MajorHealth Technology Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA. | Health Technology |
KPMG LLP
 KPMG LLP Miscellaneous Commercial ServicesCommercial Services KPMG LLP engages in the provision of audit, tax, and advisory services. It serves the banking and capital markets, building, construction and real estate, consumer and retail, energy, natural resources and chemicals, financial services, government and public sector, healthcare and life sciences, industrial manufacturing, insurance, media and entertainment, private equity, technology, telecommunications, and venture capital industries. The company was founded in 1987 and is headquartered in New York, NY. | Commercial Services |
Genetic Therapy, Inc.
 Genetic Therapy, Inc. Miscellaneous Commercial ServicesCommercial Services Genetic Therapy, Inc. develops human gene therapy products for the treatment of genetic and acquired diseases. The company also conducts research on human gene development. Genetic Therapy was founded by M. James Barrett in May 1986 and is headquartered in Gaithersburg, MD. | Commercial Services |
| Alex. Brown & Sons, Inc. | Finance |
Senseonics, Inc.
 Senseonics, Inc. Electronic ComponentsElectronic Technology Senseonics, Inc. develops transformative glucose monitoring products. It develops Senseonics continuous glucose monitoring system, an implantable continuous glucose monitoring system, which includes a miniaturized sensor and receiver that is inserted into the subcutaneous space under the skin to wirelessly transmit glucose levels to an external receiver. The company was founded by Michael James Barrett and Arthur E. Colvin in 1996 and is headquartered in Germantown, MD. | Electronic Technology |
| March of Dimes of Maryland | |
Predictive Biosciences, Inc.
Predictive Biosciences, Inc. Medical/Nursing ServicesHealth Services Predictive Biosciences is a fully-integrated developer of novel molecular diagnostic cancer assays, and a subspecialty, urology-focused provider of anatomic pathology laboratory products and services. The Company pioneered the Clinical Intervention Determining Diagnostic (CIDD) and Multi-Analyte Diagnostic Readout (MADR) approaches to cancer management, leveraging its portfolio of patented biomarkers and clinical algorithms. Based on these approaches, the Company is building a unique portfolio of assays that enable physicians to reliably determine the presence or absence of cancer with very high levels of confidence. Predictive Biosciences' first tests are targeted toward the growing bladder cancer and prostate cancer survivor populations and the large number of individuals undergoing clinical workups for these malignancies. Predictive Biosciences' corporate headquarters and innovation center is located in Lexington, Massachusetts. The Company's commercial division, OncoDiagnostic Laboratory (ODL), is located in Cleveland, Ohio. ODL is a Clinical Laboratory Improvement Act (CLIA)-certified anatomic pathology and molecular diagnostics lab with a national sales force serving urologists, gastroenterologists, dermatologists, gynecologists, and other subspecialty physicians. Founded in 2006, Predictive Biosciences is privately funded by Flybridge Capital Partners, Highland Capital Partners, Kaiser Permanente Ventures and New Enterprise Associates. | Health Services |
- Stock Market
- Insiders
- Marc R. Schneebaum